Emendo Biotherapeutics

About

Emendo Biotherapeutics develops next-generation gene-editing tools for genetic disorders, addressing technological gaps for realizing the promise of gene therapy.

Emendo genome-editing technology can repair and eliminate genetic mutations in living cells that cause serious diseases or disorders. Emendo's gene-editing solutions are recombination based, highly specific, and have zero off-target effect.

Sectors & technology

Primary sector

Health Tech & Life Sciences

Sub-sectors

Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development

Technologies

BiologicalsGenes

Target customers

Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticals

Business model

B2B

Emendo Biotherapeutics — Full Company Profile (machine-readable)

DNA Correction and Genome-editing Platforms

About

Emendo Biotherapeutics develops next-generation gene-editing tools for genetic disorders, addressing technological gaps for realizing the promise of gene therapy. Emendo genome-editing technology can repair and eliminate genetic mutations in living cells that cause serious diseases or disorders. Emendo's gene-editing solutions are recombination based, highly specific, and have zero off-target effect.

Facts

Name	Emendo Biotherapeutics
Slug	emendo-biotherapeutics
Type	Israeli Startup
Founded	2015
HQ city
HQ country	IL
Primary sector	[object Object]
Sectors	[object Object], [object Object], [object Object]
Business models	B2B
Target customers	[object Object], [object Object], [object Object], [object Object]
Status	acquired
Current stage	Acquired
Public stage	Acquired
Total raised (USD)	73,000,000
Last round	Series B (2020-01)
Website	https://www.emendobio.com/
Crunchbase ID	emendo-biotherapeutics
Israeli Companies Registrar	515372027

Funding rounds (2)

Date	Round	Amount	Lead investors	All investors	Valuation
2016-10	Series A	$12,000,000
2020-01	Series B	$61,000,000		OrbiMed, Takeda Ventures

Acquisitions (1)

Date	Target	Amount	Type
2020-12	Undisclosed	$250,000,000

Team (4)

Name	Role	LinkedIn
David Baram, Ph.D.
Shilo Ben-Zeev
Lior Izhar
Liat Shamay Zadikov

News mentions (8)

Dec 20, 2023 — www.calcalistech.com: Article
Dec 20, 2023 — www.themarker.com: Article
May 17, 2022 — www.businesswire.com: Article
Dec 22, 2021 — www.businesswire.com: Article
Dec 8, 2021 — www.businesswire.com: Article
Jan 8, 2021 — www.vivebiotech.com: Article
Dec 15, 2020 — www.businesswire.com: Article
Jan 15, 2020 — en.globes.co.il: Article

About

Funding history · 2 rounds · $73.0M total

Sectors & technology

Highlights

Tags